Once-daily , single-entity hydrocodone ( Hysingla ER tablets [ HYD ] ) is a novel formulation with abuse-deterrent properties for the management of chronic pain and represents a suitable option for those patients receiving analgesics containing the same opioid analgesic , hydrocodone .